• Online trading

Falling iron price lures investors from traditional market darlings

There is a range of trends grabbing investors’ attentions that have not been seen for some time. The big banks and miners have long been market darlings, but the falling iron ore price and dollar, as well as speculation the regulators will act to curb the boom in property markets, has prompted a substantial correction in these stocks. Volatility in equities markets, and in the dollar, has also risen sharply. Given this background, it’s likely to be a very interesting run up to Christmas in financial markets.

• Updated Oct 16, 2014
• Alexandra Cain

• Market Wrap

Acrux (ACR)

Morningstar recommends a ‘hold’ position on drug company Acrux, with a high fair value uncertainty on its price. The fair value expectation at present is $2.00.

• Updated Sep 24, 2014
• Su-Lin Tan

• Street Talk

ASX200 shorts position slides: CBA 

CBA notes the aggregate shorts position eased to 1.23 per cent of the S&P/ASX200 market capitalisation between 15 and 22 August, reversing the previous week’s increase.

• Updated Aug 29, 2014
• Sarah Thompson | Anthony Macdonald | Gretchen Friemann

Going short may signal a Waterloo

Philip Baker | Short selling can be a risky strategy. But it doesn’t stop investors from looking for overpriced stocks to sell rather than spend their time combing the list for underpriced stocks to buy.

• Updated Aug 6, 2014
• Philip Baker

Lang Walker claims big name in biotech board fight

Billionaire property developer Lang Walker’s quest to shake up the board of troubled pain drug developer QRxPharma has been more successful than first imagined, following the resignation of chairman Peter Farrell and three directors ahead of Wednesday’s shareholder meeting.

• Jul 9, 2014
• Jessica Gardner

• Investment banking

Credit Suisse sounds warning on heavily shorted stocks

Beware heavily shorted stocks heading into reporting season, Credit Suisse’s quantitative analysts have warned clients, with crowded trades prone to falling apart on better-than-expected news.

• Updated Jul 7, 2014
• Sarah Thompson, Anthony Macdonald and Gretchen Friemann

Acrux faces testosterone challenges

The testosterone replacement therapy market faces a gauntlet of challenges that could crush investors in biotechnology company Acrux.

• Jul 5, 2014
• Jessica Gardner

• Investment banking

Farrell calls Walker naive in QRxPharma battle

QRxPharma chairman Peter Farrell says the embattled pain drug developer has faltered due to the US regulator’s shifted goalposts and that disgruntled shareholder Lang Walker is naive if he thinks he can do better.

• Updated Jun 10, 2014
• Jessica Gardner

• Market Wrap

Caution ahead of ECB meet sees ASX slide

Proof that Australia’s economy performed better than expected in the first quarter of 2014 was not enough to buoy the sharemarket as stocks sold off, with global investors cautious ahead of a key ECB meeting.

• Updated Jun 5, 2014
• Sally Rose

QrXPharma board faces spill as it mulls quitting

Pain drug developer QrXPharma has urged shareholders to vote against a spill of two directors proposed by investor Lang Walker, while also flagging it was considering giving up on its technology.

• Updated Jun 3, 2014
• Jessica Gardner

Lang Walker pushes for QrXPharma board upheaval

Fresh from a multimillion-dollar loss on his investment in pain drug developer QrXPharma, rich list property developer Lang Walker is trying to eject founder Gary Pace and chairman Peter Farrell.

• Updated May 15, 2014
• Jessica Gardner

Rich list names hurt by cruel April for biotech stocks

In April almost $1 billion was wiped from the combined market value of four well-regarded companies: Acrux, Mesoblast, QrXPharma and Prana Biotechnology, dragging down equally well known names such as Waislitz and Liberman.

• Updated May 5, 2014
• Jessica Gardner

Acrux falls 15pc on sales warning

Drug delivery company Acrux has warned it is at risk of missing its next milestone payment from distributor Eli Lilly as concerns about a potential link between testosterone replacement therapy and heart failure hurt US sales.

• Updated Apr 29, 2014
• Jessica Gardner

• Hospitals

How to pick the next hot biotechnology stock

It’s a harsh but true assessment that many investors don’t understand biotechnology. So what hope is there for retail investors to profit from the next wonder drug?

• Updated Apr 11, 2014
• Jessica Gardner

• Market Wrap

Acrux Ltd (ACR)

Morningstar has a “hold” recommendation on Acrux after analysts met with management and reviewed growth assumptions for the company’s products.

• Updated Mar 7, 2014
• Elise Shaw